Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.
Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.
复制标题
DOI：
10.1136/gutjnl-2014-307990
复制
发表时间：
2015-05
期刊：
影响因子：
24.5
通讯作者：
Korangy F
中科院分区：
文献类型：
--
作者：
Greten TF;Wang XW;Korangy F
最近批准的两种免疫检查点抑制剂用于治疗恶性黑色素瘤引起了医生和基础科学家的极大兴趣，他们正在寻找胃肠道癌症的新疗法。慢性炎症被认为是肝细胞癌（HCC）发展的主要风险因素，并使这种类型的癌症成为基于免疫的治疗方法的潜在理想靶点。免疫应答在HCC患者中的关键作用的进一步证据来自免疫特征和谱预测患者的结果以及可以检测到肿瘤诱导的自发抗肿瘤免疫的事实。此外，消融治疗可导致不同免疫细胞亚群的数量、表型和功能的变化，这与患者的存活率相关。已经开发了各种HCC特异性小鼠模型，这提高了我们对肝癌发生和肿瘤-免疫细胞相互作用的理解，并导致了新的基于免疫的治疗方法的发展，目前正在临床前和早期临床环境中进行评估。免疫检查点阻断沿着过继免疫细胞疗法和疫苗方法目前正在单独或与其他治疗组合进行评估。在这里，我们提供了一个概述免疫治疗的基本原理在肝癌，总结正在进行的研究，并提供一个基于免疫的方法在肝癌患者的前景。
The recent approval of two immune checkpoint inhibitors for the treatment of malignant melanoma has sparked great interest by physicians and basic scientists searching for novel therapeutics for GI cancer. Chronic inflammation is recognised as a major risk factor for the development of hepatocellular carcinoma (HCC) and makes this type of cancer a potentially ideal target for an immune based treatment approach. Further evidence for a critical role of immune responses in patients with HCC is derived from the fact that immune signatures and profiles predict patients’ outcome as well as the fact that tumour-induced spontaneous antitumour immunity can be detected. In addition ablative therapies can lead to changes in the number, phenotype and function of different immune cell subsets, which correlate with patients’ survival. Various HCC-specific mouse models have been developed, which improve our understanding of hepatocarcinogenesis and tumour-immune cell interactions, and lead to the development of novel immune based treatment approaches, which are currently being evaluated in preclinical and in early clinical settings. Immune checkpoint blockade along with adoptive immune cell therapy and vaccine approaches are currently being evaluated either alone or in combination with other treatments. Here, we provide an overview for the rationale of immunotherapy in HCC, summarise ongoing studies and provide a perspective for immune based approaches in patients with HCC.
登录
查看更多内容
影响因子：
25.7
作者：
Cany, Jeannette;Barteau, Benoit;Conchon, Sophie
通讯作者：
Conchon, Sophie
影响因子：
24.5
作者：
Chew V;Chen J;Lee D;Loh E;Lee J;Lim KH;Weber A;Slankamenac K;Poon RT;Yang H;Ooi LL;Toh HC;Heikenwalder M;Ng IO;Nardin A;Abastado JP
通讯作者：
Abastado JP
DOI：
10.1016/j.bpg.2014.08.007
发表时间：
2014-10-01
影响因子：
3.2
作者：
Bosetti, Cristina;Turati, Federica;La Vecchia, Carlo
通讯作者：
La Vecchia, Carlo
影响因子：
12.6
作者：
Castro, Felipe A.;Liu, Xiangdong;Hemminki, Kari
通讯作者：
Hemminki, Kari
DOI：
10.1056/nejmoa1200694
发表时间：
2012-06-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Brahmer JR;Tykodi SS;Chow LQ;Hwu WJ;Topalian SL;Hwu P;Drake CG;Camacho LH;Kauh J;Odunsi K;Pitot HC;Hamid O;Bhatia S;Martins R;Eaton K;Chen S;Salay TM;Alaparthy S;Grosso JF;Korman AJ;Parker SM;Agrawal S;Goldberg SM;Pardoll DM;Gupta A;Wigginton JM
通讯作者：
Wigginton JM